Pfizer

News

Vydura is first NICE-backed oral GPCR for acute migraine

Pfizer's Vydura has become the first drug in the oral GPCR receptor antagonist class to be recommended for routine NHS use as a treatment for acute migraine.

News

EU clears review of Xtandi in earlier-stage prostate cancer

The EMA will kick off a review of Astellas and Pfizer's prostate cancer therapy Xtandi in an earlier-stage form of the cancer, which if approved could give the product a l

News

FDA clears new Pfizer, Moderna COVID jabs as cases tick up

The FDA has authorised updated versions of Pfizer/BioNTech and Moderna's mRNA-based COVID-19 vaccines targeting the XBB.1.5 subvariant, in time for the start of a new autu

News

Moderna, Pfizer say COVID jabs work against BA.2.86

Moderna and Pfizer have both said that updated versions of their COVID-19 vaccines work against the highly mutated BA.2.86 variant, also known as Pirola, which is being cl

News

Pfizer's tornado-hit plant will soon restart production

Pfizer has confirmed that its Rocky Mount facility in North Carolina, hit by a tornado in July, will be back in operation later this year.

News

FDA clears Pfizer's Abrysvo as first maternal RSV vaccine

Pfizer's respiratory syncytial virus (RSV) vaccine Abrysvo has become the first to be approved by the FDA for use in pregnancy to protect newborns and infants from lower r

Vydura is first NICE-backed oral GPCR for acute migraine

EU clears review of Xtandi in earlier-stage prostate cancer

FDA clears new Pfizer, Moderna COVID jabs as cases tick up

Moderna, Pfizer say COVID jabs work against BA.2.86

Pfizer's tornado-hit plant will soon restart production

FDA clears Pfizer's Abrysvo as first maternal RSV vaccine

Ambrosia's sweet $100m round, and other biofinancings

Using AI-driven synthetic personas to take your insights fur...

Pfizer

Editor's Picks